Anika Therapeutics Inc (ANIK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $179.50M
Last updated: Nov 17, 2026 at 11:04 AM ET
Anika Therapeutics Inc (ANIK) Earnings: Report Dates and Results
Anika Therapeutics (ANIK) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Anika Therapeutics reported EPS of -$0.01, below the $0.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ANIK has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 92.3% below the $0.13 reported for the quarter ended Dec 31, 2025.
ANIK Earnings Call
The latest ANIK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, ANIK beat 23, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $30.59M, up 10.0% from $27.82M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.01 | $0.02 | N/A | -150.00% | Miss | N/A | 1 | 1 up, 0 down | Nov 6, 2026 | $30.59M |
| Jun 30, 2026 | $0.30 | -$0.19 | N/A | +257.89% | Beat | N/A | 1 | 0 up, 1 down | Jul 29, 2026 | $32.61M |
| Mar 31, 2026 | $0.27 | -$0.16 | N/A | +268.75% | Beat | N/A | 1 | 0 up, 1 down | Apr 29, 2026 | $29.61M |
| Dec 31, 2025 | $0.13 | -$0.19 | N/A | +168.42% | Beat | N/A | 1 | 0 up, 1 down | Feb 26, 2026 | $30.61M |
| Sep 30, 2025 | -$0.17 | -$0.19 | N/A | +10.53% | Beat | N/A | 1 | 0 up, 1 down | Nov 5, 2025 | $27.82M |
| Jun 30, 2025 | -$0.13 | -$0.13 | -$0.13 - -$0.13 | 0.00% | In line | -176.5% | 1 | 0 up, 1 down | Jul 30, 2025 | $28.22M |
| Mar 31, 2025 | -$0.06 | $0.09 | $0.09 - $0.09 | -166.67% | Miss | -166.7% | 1 | 0 up, 1 down | May 9, 2025 | $26.17M |
| Dec 31, 2024 | -$0.14 | -$0.11 | N/A | -27.27% | Miss | N/A | 1 | 1 up, 1 down | Mar 12, 2025 | $30.60M |
| Sep 30, 2024 | -$0.25 | $0.30 | N/A | -183.33% | Miss | N/A | 2 | 0 up, 0 down | Oct 31, 2024 | $29.56M |
| Jun 30, 2024 | $0.17 | $0.20 | N/A | -15.00% | Miss | +183.3% | 3 | 0 up, 0 down | Aug 8, 2024 | $30.72M |
| Mar 31, 2024 | $0.09 | $0.05 | N/A | +80.00% | Beat | N/A | 3 | 0 up, 1 down | May 8, 2024 | $29.02M |
| Dec 31, 2023 | -$4.30 | -$0.26 | -$0.32 - -$0.21 | N/A | N/A | N/A | 3 | 0 up, 0 down | Mar 13, 2024 | N/A |
| Sep 30, 2023 | -$0.45 | -$0.35 | -$0.43 - -$0.33 | -28.57% | Miss | N/A | 3 | 0 up, 0 down | Nov 2, 2023 | $41.47M |
| Jun 30, 2023 | $0.06 | -$0.32 | N/A | +118.75% | Beat | N/A | 2 | 0 up, 0 down | Aug 8, 2023 | $44.30M |
| Mar 31, 2023 | -$0.36 | -$0.32 | -$0.36 - -$0.25 | -12.50% | Miss | N/A | 3 | 0 up, 0 down | May 9, 2023 | $37.92M |
| Dec 31, 2022 | -$0.34 | -$0.24 | -$0.30 - -$0.20 | -41.67% | Miss | N/A | 3 | 0 up, 0 down | Mar 6, 2023 | N/A |
| Sep 30, 2022 | -$0.05 | -$0.23 | N/A | +78.26% | Beat | -200.0% | 3 | 0 up, 0 down | Nov 8, 2022 | $40.26M |
| Jun 30, 2022 | -$0.12 | -$0.21 | -$0.31 - -$0.11 | +42.86% | Beat | -233.3% | 3 | 0 up, 0 down | Aug 3, 2022 | $39.66M |
| Mar 31, 2022 | -$0.11 | -$0.31 | -$0.42 - -$0.31 | +64.52% | Beat | -283.3% | 2 | 0 up, 0 down | May 5, 2022 | $36.69M |
| Dec 31, 2021 | -$0.40 | -$0.25 | -$0.34 - -$0.16 | -60.00% | Miss | -433.3% | 4 | 1 up, 0 down | Mar 8, 2022 | $35.82M |
| Sep 30, 2021 | $0.05 | $0.05 | N/A | 0.00% | In line | 0.0% | 3 | N/A | Nov 4, 2021 | $39.54M |
| Jun 30, 2021 | $0.09 | -$0.03 | N/A | +400.00% | Beat | 0.0% | 3 | N/A | Aug 5, 2021 | $38.15M |
| Mar 31, 2021 | $0.06 | $0.01 | N/A | +500.00% | Beat | -86.7% | 2 | N/A | May 6, 2021 | $34.29M |
| Dec 31, 2020 | $0.12 | $0.14 | N/A | -14.29% | Miss | -72.1% | 2 | N/A | Mar 4, 2021 | $32.69M |
| Sep 30, 2020 | $0.05 | $0.13 | -$0.15 - $0.13 | -61.54% | Miss | -92.2% | 2 | N/A | Nov 4, 2020 | $31.69M |
| Jun 30, 2020 | $0.09 | -$0.14 | -$0.42 - -$0.07 | +164.29% | Beat | -86.6% | 2 | N/A | Jul 30, 2020 | $30.68M |
| Mar 31, 2020 | $0.45 | $0.22 | N/A | +104.55% | Beat | +45.2% | 2 | N/A | May 7, 2020 | $35.40M |
| Dec 31, 2019 | $0.43 | $0.42 | $0.38 - $0.44 | +2.38% | Beat | -20.4% | 3 | N/A | Feb 20, 2020 | $29.77M |
| Sep 30, 2019 | $0.64 | $0.39 | $0.37 - $0.42 | +64.10% | Beat | +20.8% | 3 | N/A | Oct 24, 2019 | $29.70M |
| Jun 30, 2019 | $0.67 | $0.40 | $0.36 - $0.43 | +67.50% | Beat | -1.5% | 4 | N/A | Jul 24, 2019 | $30.42M |
| Mar 31, 2019 | $0.31 | $0.20 | $0.15 - $0.24 | +55.00% | Beat | N/A | 4 | N/A | May 2, 2019 | $24.72M |
| Dec 31, 2018 | $0.54 | $0.33 | $0.25 - $0.39 | +63.64% | Beat | +42.1% | 4 | N/A | Feb 21, 2019 | $26.96M |
| Sep 30, 2018 | $0.53 | $0.31 | $0.27 - $0.35 | +70.97% | Beat | +15.2% | 4 | N/A | Oct 24, 2018 | $26.79M |
| Jun 30, 2018 | $0.68 | $0.29 | $0.27 - $0.44 | +134.48% | Beat | -10.5% | 4 | N/A | Jul 25, 2018 | $30.55M |
| Mar 31, 2018 | -$0.46 | $0.25 | -$0.14 - $0.26 | -284.00% | Miss | -224.3% | 4 | N/A | May 2, 2018 | $21.26M |
| Dec 31, 2017 | $0.38 | $0.44 | $0.37 - $0.48 | -13.64% | Miss | -29.6% | 4 | N/A | Feb 21, 2018 | $29.39M |
| Sep 30, 2017 | $0.46 | $0.42 | $0.42 - $0.51 | +9.52% | Beat | -22.0% | 2 | N/A | Oct 25, 2017 | $27.18M |
| Jun 30, 2017 | $0.76 | $0.44 | $0.42 - $0.47 | +72.73% | Beat | +33.3% | 3 | N/A | Jul 26, 2017 | $33.46M |
| Mar 31, 2017 | $0.37 | $0.38 | N/A | -2.63% | Miss | -17.8% | N/A | N/A | May 3, 2017 | $23.39M |
| Dec 31, 2016 | $0.54 | $0.53 | N/A | +1.89% | Beat | -25.0% | N/A | N/A | Feb 15, 2017 | $28.73M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.23, after -$0.13 the year before. It was $2.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.23 | N/A |
| Dec 31, 2024 | -$0.13 | N/A |
| Dec 31, 2023 | -$5.05 | N/A |
| Dec 31, 2022 | -$0.62 | N/A |
| Dec 31, 2021 | -$0.20 | -128.2% |
| Dec 31, 2020 | $0.71 | -65.4% |
| Dec 31, 2019 | $2.05 | +58.9% |
| Dec 31, 2018 | $1.29 | -34.5% |
| Dec 31, 2017 | $1.97 | -8.4% |
| Dec 31, 2016 | $2.15 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,013 | 6 | |
| 2026Q2 | Jun 30, 2026 | 4,995 | 6 | |
| 2026Q1 | Mar 31, 2026 | 4,486 | 6 | |
| 2025Q4 | Dec 31, 2025 | 5,124 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,135 | 5 | |
| 2025Q2 | Jun 30, 2025 | 5,202 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,510 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,488 | 6 |
2026Q3 Earnings Call
Opening remarks
Matthew Hall Executive Director of Corporate Development and Investor Relations Good morning. Thank you for joining us for Anika's third quarter 2026 earnings call. I am Matthew Hall, Anika's Executive Director of Corporate Development and Investor Relations. Our earnings press release was issued earlier this morning and is available on our Investor Relations website, as are our supplementary PowerPoint slides that will be used for discussion today. With me on the call are Steve Griffin, President and Chief Executive Officer, and Ian W. McLeod, Senior Vice President, Chief Accounting Officer, and Treasurer. They will present our third quarter 2026 financial results and business highlights. Please take a moment to open the slide presentation and refer to slide 2. Before we begin, please understand that certain statements made during the call today constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance, or achievements. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. Please also see our most recent SEC filings for more information about risks that could affect our performance. In addition, during the call, we may refer to several adjusted or non-GAAP financial measures, which may include adjusted gross margin, adjusted EBITDA, adjusted net income from continuing operations, and adjusted earnings per share from continuing operations. These are used in addition to results presented in accordance with GAAP financial measures. We believe that non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial measures and the reconciliation of GAAP measures, they provide an even more complete understanding of our business. A reconciliation of these adjusted non-GAAP financial results to the most comparable GAAP measurements is available at the end of the presentation slide deck and in our third quarter 2026 press release. With that, I will turn the call over to Steve to discuss the quarter and our progress. Steve?
Stephen D. Griffin President and Chief Executive Officer Good morning, everyone, and thank you for joining us. Our third quarter performance marked another positive step in building a stronger, more profitable Anika. Revenue grew 10%, with growth in both our commercial and OEM channels. We improved gross margin year over year, expanded adoption of Integrity, completed key manufacturing and pipeline milestones, and strengthened a long-term partnership that will contribute to future growth. These results also reinforce the strategic focus we have built around our core hyaluronic acid platform and the opportunities it creates across our business.
Frequently Asked Questions About ANIK
When is Anika Therapeutics's next earnings date?
Anika Therapeutics's next earnings report is expected for Feb 24, 2027.
Did ANIK beat earnings estimates last quarter?
No. Anika Therapeutics reported EPS of -$0.01 for the quarter ended Sep 30, 2026, below the $0.02 estimate by 150.00%.
What EPS do analysts expect from ANIK next quarter?
The consensus EPS estimate for Anika Therapeutics for the quarter ending Dec 31, 2026 is $0.01 from 4 analysts, with estimates from $0.00 to $0.01.
How often does ANIK beat earnings estimates?
Anika Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +45.21%.
ANIK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors